Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.

Siddharth M PatelYu Mi KangKyungAh ImBrendon L Neuen Stefan D Anker Deepak L Bhatt Javed Butler David Z I Cherney Brian Lee Claggett Robert A Fletcher William G Herrington Catherine M Viscoli Meg J Jardine Kenneth W Mahaffey Darren K McGuire John Joseph Valentine McMurray Bruce C Neal Milton Packer Vlado Perkovic Scott D Solomon Natalie Staplin Muthiah Vaduganathan Christoph Wanner David Collins Wheeler Faiez Zannad Yujie Zhao Hiddo J Lambers Heerspink Marc S Sabatine Stephen D Wiviott

Published in: Circulation (2024)

SGLT2i reduce the risk of MACE across a broad range of patients irrespective of atherosclerotic cardiovascular disease, diabetes, kidney function, or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of cardiovascular death, particularly HF death and sudden cardiac death, without a significant effect on myocardial infarction in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.

Keyphrases